Sugi Predict

Sugi Predict / Compounds / SCHEMBL780241

SCHEMBL780241

SCHEMBL780241

CC(C)(C)OC(=O)N1CCN(C(=O)OC(C)(C)C)C(C=O)C1

nearest known ligand 0.44

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.44
▸ MEN1 O00255 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MAPT P10636 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ USP2 O75604 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ SETD7 Q8WTS6 1/20 0.39
▸ RECQL P46063 1/20 0.38
▸ EPHX1 P07099 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31377192 1.00 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL21838817 1.00 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL22167880 0.93 NR1H2 (0.38) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL22342643 0.91 NR1H2 (0.42) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL5718903 0.91 HSD17B10 (0.39) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL1943071 0.91 NR1H2 (0.42) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL17068153 0.84 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL18426233 0.84 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL18211868 0.84 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL2277430 0.83 NR1H2 (0.44) NR1H2MEN1ALDH1A1MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof CIT THERAPEUTICS, INC. (US) 2026-04-28 — — US disclosed
US-20260035367-A1 PKC-Theta Modulators CELGENE CORPORATION (US) 2026-02-05 — — US disclosed
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF CIT THERAPEUTICS LLC 2024-10-31 — — US disclosed
US-20240262821-A1 PKC-Theta Modulators EXSCIENTIA AL LIMITED (GB) 2024-08-08 — — US disclosed
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 — — EP disclosed
EP-4333982-A1 PKC-THETA MODULATORS Exscientia Al Limited (GB) 2024-03-13 — — EP disclosed
CN-117355522-A PKC-theta modulators 爱智药人工智能有限公司 2024-01-05 — — CN disclosed
WO-2023146989-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed
WO-2023004376-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2023-01-26 — — WO disclosed
WO-2022234298-A1 PKC-THETA MODULATORS EXSCIENTIA AI LIMITED (GB) 2022-11-10 — — WO disclosed
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH 2008-02-28 — — US disclosed
WO-2007146066-A2 NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF CRITICAL THERAPEUTICS, INC. (US) 2007-12-21 — — WO disclosed
WO-2007146066-A2 NOVEL PIPERAZINES, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF CRITICAL THERAPEUTICS, INC. (US) 2007-12-21 — — WO disclosed
US-7074798-B2 Xanthine derivative and DPPIV inhibitor EISAI CO., LTD (JP) 2006-07-11 — — US disclosed
EP-1338595-B1 Xanthine derivatives as DPP-IV inhibitors EISAI CO LTD (JP) 2006-05-03 — — EP disclosed
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 — — US disclosed
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor EISAI CO., LTD. (JP) 2004-04-29 — — US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 — — US disclosed
EP-1338595-A2 Xanthine derivatives as DPP-IV inhibitors Eisai Co., Ltd. (JP) 2003-08-27 — — EP disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor DPP4, DPP9, DPP7 NR1H2 952/4885MEN1 3419/4885ALDH1A1 112/4885
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction F2, CYC1, SULT2A1 NR1H2 1095/4885MEN1 2216/4885ALDH1A1 1316/4885
US-20260035367-A1 PKC-Theta Modulators PRKAR2B, PRKAR2A, PRKCD NR1H2 65/4885MEN1 3522/4885ALDH1A1 4459/4885
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF SUMO1, SUMO3, SUMO2 NR1H2 3556/4885MEN1 2517/4885ALDH1A1 1529/4885
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof SUMO1, SUMO3, PSMB6 NR1H2 2552/4885MEN1 3270/4885ALDH1A1 1299/4885
US-20240262821-A1 PKC-Theta Modulators PRKCQ, PRKCH, PRKCE NR1H2 381/4885MEN1 4029/4885ALDH1A1 4352/4885
US-20080051415-A1 Novel piperazines, pharmaceutical compositions and methods of use thereof CHRNA7, CHRNA5, CHRNA2 NR1H2 717/4885MEN1 4856/4885ALDH1A1 1032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.